PT717638E - CYCLODEXTRINES FOR THE REDUCTION OF EXTRAVASE TOXICITY CAUSED BY CYTOTOXIC SUBSTANCES - Google Patents
CYCLODEXTRINES FOR THE REDUCTION OF EXTRAVASE TOXICITY CAUSED BY CYTOTOXIC SUBSTANCESInfo
- Publication number
- PT717638E PT717638E PT94927983T PT94927983T PT717638E PT 717638 E PT717638 E PT 717638E PT 94927983 T PT94927983 T PT 94927983T PT 94927983 T PT94927983 T PT 94927983T PT 717638 E PT717638 E PT 717638E
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- cytotoxic
- cyclodextrin
- ulceration
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11672493A | 1993-09-03 | 1993-09-03 | |
US08/297,249 US5602112A (en) | 1992-06-19 | 1994-08-26 | Pharmaceutical formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
PT717638E true PT717638E (en) | 2002-07-31 |
Family
ID=26814548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT94927983T PT717638E (en) | 1993-09-03 | 1994-09-02 | CYCLODEXTRINES FOR THE REDUCTION OF EXTRAVASE TOXICITY CAUSED BY CYTOTOXIC SUBSTANCES |
Country Status (13)
Country | Link |
---|---|
US (6) | US5602112A (en) |
EP (1) | EP0717638B1 (en) |
JP (1) | JPH09502185A (en) |
AT (1) | ATE214290T1 (en) |
AU (1) | AU7718694A (en) |
CA (1) | CA2172159C (en) |
DE (1) | DE69430126T2 (en) |
DK (1) | DK0717638T3 (en) |
ES (1) | ES2171462T3 (en) |
HU (1) | HUT73778A (en) |
IL (1) | IL110825A0 (en) |
PT (1) | PT717638E (en) |
WO (1) | WO1995006485A1 (en) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US20040014695A1 (en) * | 1992-06-19 | 2004-01-22 | Supergen, Inc. | Pharmaceutical formulation |
DE69434304T2 (en) * | 1993-03-26 | 2005-12-29 | Merkus, Franciscus Wilhelmus H.M. | Pharmaceutical compositions for the intranasal administration of dihydroergotamine |
AU737078C (en) | 1996-05-24 | 2002-05-02 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
US6566353B2 (en) * | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
BR9713661A (en) | 1996-12-30 | 2000-10-24 | Battelle Memorial Institute | Formulation and method for the treatment of neoplasms by inhalation |
HUP9701945A3 (en) * | 1997-11-10 | 2000-04-28 | Hexal Ag | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
GB9921958D0 (en) | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
GB9921954D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
US6770621B2 (en) * | 2000-05-02 | 2004-08-03 | Theravance, Inc. | Polyacid glycopeptide derivatives |
ATE416791T1 (en) * | 2000-05-02 | 2008-12-15 | Theravance Inc | COMPOSITION CONTAINING A CYCLODEXTRIN AND A GLYCOPEPTIDE ANTIBIOTIC |
US6828299B2 (en) | 2000-06-22 | 2004-12-07 | Theravance, Inc. | Polyhydroxy glycopeptide derivatives |
UA75083C2 (en) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Derivatives of glycopeptidephosphonates |
WO2001098327A2 (en) * | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Glycopeptide carboxy-saccharide derivatives |
US6872804B2 (en) * | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
US6468989B1 (en) * | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
PE20020300A1 (en) * | 2000-08-22 | 2002-05-10 | Pharmacia Corp | COMPOSITION OF SOLUTION OF AN ANTIBIOTIC DRUG BASED ON OXAZOLIDINONE WITH IMPROVEMENT OF DRUG LOAD |
IT1318689B1 (en) * | 2000-09-12 | 2003-08-27 | Pharmacia & Upjohn Spa | USE OF ARGININE IN THE PREPARATION OF A MEDICATION FOR THE PREPARATION AND TREATMENT OF THE SIDE EFFECTS ASSOCIATED WITH |
US6884885B2 (en) | 2000-12-21 | 2005-04-26 | Cerestar Holding B.V. | Production of cyclodextrin complexes |
EP1389090A2 (en) * | 2001-04-26 | 2004-02-18 | Board of Regents, The University of Texas System | Diagnostic imaging compositions, their methods of synthesis and use |
US6528076B2 (en) | 2001-07-06 | 2003-03-04 | Magic Herb Corp. | Topical compositions and methods for treating pain |
GB0127677D0 (en) * | 2001-11-19 | 2002-01-09 | Vianex S A | Inclusion complex |
US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
US6828311B2 (en) | 2002-05-29 | 2004-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Formulation for the parenteral application of a sodium channel blocker |
CA2497898C (en) * | 2002-09-05 | 2012-02-07 | Bharat Serums & Vaccines Ltd. | Liquid stable composition of oxazaphosphorine with mesna |
US7157446B2 (en) * | 2003-05-02 | 2007-01-02 | Bristol Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
JP5021318B2 (en) * | 2004-01-30 | 2012-09-05 | ファイザー・プロダクツ・インク | Antibacterial preservatives for achieving multi-dose formulations using β-cyclodextrin in liquid dosage forms |
US20070093449A1 (en) * | 2005-10-14 | 2007-04-26 | De Porre Peter M R | Novel IV formulation of tipifarnib |
CN100486645C (en) | 2006-09-12 | 2009-05-13 | 南京师范大学 | Medicine composition containing cyclodextrin included taxol and its preparation process |
CN100411688C (en) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | Medicine composition containing cyclodextrin/polyene taxol and its prepn process |
MX2009004214A (en) | 2006-10-20 | 2009-05-11 | Icos Corp | Compositions of chk1 inhibitors. |
US20100021400A1 (en) * | 2008-04-25 | 2010-01-28 | Rhode Island Hospital | Active Sunscreen Composition |
WO2010097700A1 (en) | 2009-02-25 | 2010-09-02 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
US20100311838A1 (en) | 2009-05-29 | 2010-12-09 | Pipkin James D | Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
US20110015245A1 (en) * | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
US8389558B2 (en) * | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
TWI438009B (en) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | Taxane pro-emulsion formulations and methods making and using the same |
EP2566474B1 (en) | 2010-05-03 | 2017-11-15 | Teikoku Pharma USA, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
EP2758052B9 (en) * | 2011-09-18 | 2019-03-27 | Euro-Celtique S.A. | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide |
TWI573792B (en) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | Novel therapeutic agents |
JO3685B1 (en) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | Non-aqueous taxane nanodispersion formulations and methods of using the same |
US20160022720A1 (en) * | 2013-08-02 | 2016-01-28 | Children's Hospital Medical Center | Compositions and methods for treating disease states associated with activated t cells and/or b cells |
WO2015061206A2 (en) | 2013-10-21 | 2015-04-30 | North Carolina State University | Methods and constructs for compound delivery |
RU2587716C2 (en) * | 2014-01-14 | 2016-06-20 | Борис Игоревич Круглый | Stable pharmaceutical composition based on actinomycin d for injections |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
CA3040155C (en) | 2016-10-11 | 2024-01-16 | Euro-Celtique S.A. | Compound for use in the treatment of hodgkin lymphoma |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5735189B2 (en) * | 1972-01-06 | 1982-07-27 | ||
US4024223A (en) * | 1972-11-11 | 1977-05-17 | Teijin Limited | Stripe composition and method of reducing smell associated therewith |
JPS53136513A (en) * | 1977-05-06 | 1978-11-29 | Ono Pharmaceut Co Ltd | Stabilization of prostaglandin-x-related compounds |
HU176215B (en) * | 1978-01-27 | 1981-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1 |
JPS54115368A (en) * | 1978-03-01 | 1979-09-07 | Ono Pharmaceut Co Ltd | Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent |
IT1113341B (en) * | 1978-03-31 | 1986-01-20 | Ono Pharmaceutical Co | ANALOGUES OF 6.9-METHANE-PGI2 |
US4352793A (en) * | 1979-04-26 | 1982-10-05 | Sumitomo Chemical Company, Limited | Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin |
JPS6033430B2 (en) * | 1980-05-12 | 1985-08-02 | 小野薬品工業株式会社 | Prostaglandin-like compounds |
EP0056995B1 (en) * | 1981-01-23 | 1986-03-26 | The Wellcome Foundation Limited | Chemical complex |
US4407795A (en) * | 1981-07-16 | 1983-10-04 | American Cyanamid Company | Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use |
JPS5813541A (en) * | 1981-07-16 | 1983-01-26 | Kureha Chem Ind Co Ltd | Cyclodextrin clathrate compound of eicosapentaenoic acid or docosahexaenoic acid |
JPS5838250A (en) * | 1981-09-01 | 1983-03-05 | Teikoku Chem Ind Corp Ltd | Composite |
JPS58126810A (en) * | 1981-12-24 | 1983-07-28 | Kaken Pharmaceut Co Ltd | Ophthalmic anti-inflammatory solution and preparation thereof |
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
JPS58177949A (en) * | 1982-04-12 | 1983-10-18 | Takeda Chem Ind Ltd | Clathrate compound of lankacidin-group antibiotic substance |
DE3315356A1 (en) * | 1982-04-30 | 1983-11-17 | Ono Pharmaceutical Co. Ltd., Osaka | USE OF PROSTAGLANDINE ANALOGS |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
US4425336A (en) * | 1982-05-24 | 1984-01-10 | Key Pharmaceuticals, Inc. | 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes |
US4424209A (en) * | 1982-06-21 | 1984-01-03 | Key Pharmaceuticals, Inc. | 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes |
JPS5910510A (en) * | 1982-07-08 | 1984-01-20 | Nippon Zenyaku Kogyo Kk | Low irritant tiamulin injection |
JPS5920230A (en) * | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | Drug containing piruprophen |
HU190818B (en) * | 1982-11-09 | 1986-11-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for producing complexes of piperonyl-butoxide-cyclodextrin |
JPS6025967A (en) * | 1983-07-21 | 1985-02-08 | Eisai Co Ltd | Tripamide clathrate compound |
US4751095A (en) * | 1983-07-28 | 1988-06-14 | Karl Curtis L | Aspartame stabilization with cyclodextrin |
JPS6081166A (en) * | 1983-10-11 | 1985-05-09 | Fujisawa Pharmaceut Co Ltd | Beta-cyclodextrin clathrate compound of 2-nitroxymethyl-6- chloropyridine and production thereof |
IT1196033B (en) * | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | COMPOUND WITH ANTI-INFLAMMATORY ACTIVITY OBTAINED BY COMPLEXATION WITH BETA-CYCLODEXTRINE AND RELATED PHARMACEUTICAL FORMULATIONS |
US4675395A (en) * | 1984-03-14 | 1987-06-23 | Seiwa Technological Laboratories Limited | Cyclodextrin inclusion compound and process for its preparation |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
JPS61207380A (en) * | 1985-03-11 | 1986-09-13 | Taiyo Yakuhin Kogyo Kk | Oral preparation of mobenzoxamine |
JPS61286318A (en) * | 1985-06-13 | 1986-12-16 | Ichiro Shibauchi | Production of bathing agent |
US4663316A (en) * | 1985-06-28 | 1987-05-05 | Warner-Lambert Company | Antibiotic clathrates and pharmaceutical compositions thereof |
US4728509A (en) * | 1985-08-19 | 1988-03-01 | Takeda Chemical Industries, Ltd. | Aqueous liquid preparation |
US4623641A (en) * | 1985-09-09 | 1986-11-18 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
JP3176716B2 (en) * | 1991-06-21 | 2001-06-18 | 武田薬品工業株式会社 | Poorly water-soluble drug composition having improved solubility |
ATE196426T1 (en) * | 1991-06-21 | 2000-10-15 | Takeda Chemical Industries Ltd | CYCLODEXTRIN COMPOSITION CONTAINING FUMAGILLOL DERIVATIVES |
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
JPH06157330A (en) * | 1992-11-27 | 1994-06-03 | Ensuiko Sugar Refining Co Ltd | Cyclodextrin clathrate of taxol, it production and use thereof |
-
1994
- 1994-08-26 US US08/297,249 patent/US5602112A/en not_active Expired - Lifetime
- 1994-08-30 IL IL11082594A patent/IL110825A0/en unknown
- 1994-09-02 HU HU9600612A patent/HUT73778A/en unknown
- 1994-09-02 AT AT94927983T patent/ATE214290T1/en active
- 1994-09-02 DK DK94927983T patent/DK0717638T3/en active
- 1994-09-02 WO PCT/US1994/009879 patent/WO1995006485A1/en active IP Right Grant
- 1994-09-02 PT PT94927983T patent/PT717638E/en unknown
- 1994-09-02 JP JP7508268A patent/JPH09502185A/en active Pending
- 1994-09-02 EP EP94927983A patent/EP0717638B1/en not_active Expired - Lifetime
- 1994-09-02 ES ES94927983T patent/ES2171462T3/en not_active Expired - Lifetime
- 1994-09-02 DE DE69430126T patent/DE69430126T2/en not_active Expired - Fee Related
- 1994-09-02 AU AU77186/94A patent/AU7718694A/en not_active Abandoned
- 1994-09-02 CA CA002172159A patent/CA2172159C/en not_active Expired - Fee Related
-
1997
- 1997-02-03 US US08/790,223 patent/US5804568A/en not_active Expired - Lifetime
-
1998
- 1998-08-28 US US09/143,412 patent/US6048845A/en not_active Expired - Lifetime
-
1999
- 1999-07-02 US US09/347,096 patent/US6218374B1/en not_active Expired - Fee Related
-
2000
- 2000-10-05 US US09/684,375 patent/US6284747B1/en not_active Expired - Fee Related
-
2001
- 2001-08-23 US US09/938,473 patent/US6583125B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6048845A (en) | 2000-04-11 |
EP0717638A1 (en) | 1996-06-26 |
DE69430126T2 (en) | 2002-08-01 |
IL110825A0 (en) | 1995-05-26 |
US6218374B1 (en) | 2001-04-17 |
CA2172159C (en) | 2003-07-29 |
ATE214290T1 (en) | 2002-03-15 |
US6284747B1 (en) | 2001-09-04 |
ES2171462T3 (en) | 2002-09-16 |
US5602112A (en) | 1997-02-11 |
US5804568A (en) | 1998-09-08 |
HU9600612D0 (en) | 1996-05-28 |
CA2172159A1 (en) | 1995-03-09 |
DK0717638T3 (en) | 2002-07-01 |
US6583125B2 (en) | 2003-06-24 |
HUT73778A (en) | 1996-09-30 |
JPH09502185A (en) | 1997-03-04 |
AU7718694A (en) | 1995-03-22 |
EP0717638B1 (en) | 2002-03-13 |
US20020058634A1 (en) | 2002-05-16 |
DE69430126D1 (en) | 2002-04-18 |
WO1995006485A1 (en) | 1995-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT717638E (en) | CYCLODEXTRINES FOR THE REDUCTION OF EXTRAVASE TOXICITY CAUSED BY CYTOTOXIC SUBSTANCES | |
AU773506B2 (en) | Antitumour synergistic composition | |
FR2708608B1 (en) | N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them. | |
WO2001072721A3 (en) | Synergistic methods and compositions for treating cancer | |
GEP19991649B (en) | Composition of Derivatives of Cyclodextrins, Clathrating Composition Comprising the Same and Pharmaceutical Composition. | |
DE69918819T2 (en) | ANTICREASIC COMPOSITION CONTAINS A SYNERGISTIC COMBINATION COMPRISING AN ANTHRACYCLINE DERIVATIVE WITH A CAMPTOTHECINE DERIVATIVE | |
CZ289570B6 (en) | Pharmaceutical formulation containing voriconazole | |
ATE238053T1 (en) | FORMULATIONS AND COMPOSITIONS OF CAMPTOTHECINE DERIVATIVES THAT ARE POORLY SOLUBLE IN WATER | |
ATE87319T1 (en) | INCLUSION COMPLEXES OF 7-ISOPROPOXY-ISOFLAVONE WITH CYCLODEXTRINS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE INCLUSION COMPLEXES. | |
CA2292359A1 (en) | Novel azalides and methods of making same | |
KR950702994A (en) | PROTEIN KINASE INHIBITORS AND RELATED COMPOUNDS COMBINED WITH TAXOL | |
YU11699A (en) | 6-substituted ketolydes having a bactericidal impact, procedures for the production thereof and their pharmaceutical preparations | |
EE200200207A (en) | Use of quinoline derivatives in the preparation of an anticancer drug, preparation of the compounds and pharmaceutical compositions containing them | |
KR987000322A (en) | Novel Anthracycline Compound Derivatives and Pharmaceutical Formulations Containing the Same (NOVEL ANTHRACYCLINE COMPOUND DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME) | |
AU678344B2 (en) | Lipophilic oligosaccharide antibiotic salt compositions | |
BR0212036A (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting metastasis or preventing recurrence of malignant tumor | |
IT1241673B (en) | INCLUSION COMPLEXES OF SILIBININ WITH CYCLODESTRINE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
WO1996023771A3 (en) | Platelet aggregation inhibitors | |
WO1999057125A3 (en) | Hygromycin a derivatives | |
DE69805860T2 (en) | WATER-SOLUBLE SIMILAR COMPOUNDS AND MEDICAMENT PRE-STAGE BY PACLITAXEL | |
SV2002000211A (en) | HYGROMYCIN DERIVATIVES REF. PC10726ABCZ / BB | |
DE69902925D1 (en) | New injectable medicinal preparations containing ramoplan | |
WO2003030884A2 (en) | Use of solasonine for the treatment of skin tumors | |
BG103985A (en) | Multicyclic derivatives of erythromycin | |
WO2003030915A1 (en) | Use of solamargine for treating skin tumors |